Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1781-1800 of 2,120 trials

Advanced Ovarian Cancer: TORL-1-23 Treatment Study

We are studying the effectiveness of TORL-1-23 in women with advanced platinum-resistant ovarian cancer that expresses Claudin 6. This research aims to find new treatment options for this challenging condition.

Peritoneal CancerOvarian CancerFallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Lung Cancer: Atezolizumab vs. Atezolizumab Plus Bevacizumab

We are studying whether adding bevacizumab to atezolizumab helps patients with advanced non-small-cell lung cancer live longer than using atezolizumab alone. This trial is for those with high PD-L1 expression who have not yet received treatment.

Advanced Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Pembrolizumab for Advanced Adrenocortical Carcinoma

We are studying whether pembrolizumab can effectively treat advanced, progressive adrenocortical carcinoma. The trial also looks at its safety and how it affects patients' quality of life.

Adrenocortical Carcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Attack Recovery: Ferric Carboxymaltose Treatment

We are studying whether intravenous ferric carboxymaltose can improve survival and quality of life in iron-deficient patients who recently had a heart attack. This trial compares its effects to a placebo treatment.

Recent Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCardiologyInternal Medicine

Multiple Myeloma: Isatuximab Treatment Study

We are studying a new treatment combination for elderly patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see if this approach improves disease control and safety compared to standard treatments.

Newly Diagnosed Multiple Myeloma in Elderly Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

NSTEMI Treatment: Aspirin vs. Aspirin and Fondaparinux

We are comparing the effects of aspirin alone to a combination of aspirin and fondaparinux in patients with NSTEMI. This study aims to see which treatment is more effective and safer before invasive procedures.

Non-ST-Elevation Myocardial Infarction (NSTEMI)>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Colorectal Cancer: MK-1084 Treatment Study

We are testing a new treatment combining MK-1084, cetuximab, and chemotherapy for patients with advanced colorectal cancer. The goal is to see if this combination is safer and more effective than standard treatments.

Metastatic Colorectal CancerKRAS Mutation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

SOD1 ALS: AMT-162 Gene Therapy

We are testing a new gene therapy for adults with SOD1 amyotrophic lateral sclerosis to see if it is safe and well-tolerated. We’re also exploring its potential effects on the disease.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Higher Risk Myelodysplastic Syndrome: Lisaftoclax with Azacitidine

We are studying whether the combination of Lisaftoclax and azacitidine is more effective than a placebo with azacitidine for adults newly diagnosed with higher risk myelodysplastic syndrome. The trial will also assess safety and patient-reported outcomes.

Higher Risk Myelodysplastic SyndromeConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Rare Cancers: Domvanalimab + Zimberelimab Study

We are investigating the safety and effectiveness of a new combination therapy for patients with advanced rare cancers that have not responded to previous treatments. This trial includes several types of rare cancers, aiming to find better treatment options.

Rare Cancers>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Knee Osteoarthritis: KBP-336 Medication Study

We are testing a new medication for obese individuals with knee osteoarthritis to see if it helps reduce weight and pain. The study will also look at other symptoms and overall safety compared to a placebo.

Knee OsteoarthritisObesity6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

BOTOX® for Preventing Pancreatic Fistula After Surgery

We are studying whether BOTOX® injections before surgery can help prevent complications in patients undergoing distal pancreatectomy. This trial will assess the safety and effectiveness of this approach.

Postoperative Pancreatic Fistulas≤3 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Retinoblastoma: New Conservative Treatment Approaches

We are studying different chemotherapy and local treatment methods for children with retinoblastoma to see if they can preserve vision without using radiation. This trial includes various patient groups based on their specific conditions.

RetinoblastomaEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

T-Guard for Early Diffuse Cutaneous Systemic Sclerosis

We are studying the safety and effectiveness of T-Guard in patients with early diffuse cutaneous systemic sclerosis. This trial will help us understand how well the treatment works and how it is processed in the body.

Diffuse Systemic Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyInternal MedicineRheumatology

Lymphoma: Comparing Pneumococcal Vaccines

We are studying the effectiveness of two pneumococcal vaccines in adults with lymphoma receiving chemotherapy. This trial aims to see which vaccination strategy provides a better immune response and is safer.

Lymphoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOncology

IVF/ICSI: Optimizing Recombinant FSH Dosing

We are studying the best dose of recombinant FSH for patients undergoing IVF/ICSI to improve hormone levels and pregnancy outcomes. This research may help enhance fertility treatment success.

Female Subfertility1-2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Lung Cancer Treatment: Immunotherapy and Radiation

We are studying a new treatment combining immunotherapy and radiation for elderly or unfit patients with advanced lung cancer. The aim is to see if this approach improves survival and quality of life.

Unresectable Stage III Non-Small Cell Lung Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Myeloma Treatment: Elranatamab vs. Daratumumab

We are studying whether elranatamab combined with lenalidomide helps patients with newly diagnosed myeloma maintain remission better than daratumumab with lenalidomide after a transplant. This trial will also assess safety and quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Advanced Liver Cancer: CS1003 with Lenvatinib

We are studying a new treatment combined with lenvatinib for people with advanced liver cancer. The trial compares this combination to a placebo with lenvatinib to see which is more effective and safe.

Unresectable Advanced Liver Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHepatologyOncology

Bladder Cancer: V940 and BCG Combination Study

We are investigating whether a new treatment, V940, combined with BCG can improve outcomes for people with high-risk non-muscle invasive bladder cancer compared to BCG alone. This study will also assess the safety of all treatment options.

Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology